Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
Condition: Desmoid-Type FibromatosisInterventions: Other: Laboratory Biomarker Analysis; Other: Placebo; Other: Quality-of-Life Assessment; Drug: Sorafenib TosylateSponsor: National Cancer Institute (NCI)Recruiting - verified March 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials